Home Biosimilar Antibodies Protein Tyrosine Kinase IGF-1R Ganitumab (Anti-IGF-1R / CD221)
For research use only. Not for use in humans.

Ganitumab (Anti-IGF-1R / CD221)

Synonyms: AMG 479; Human Anti-IGF-1R Recombinant Antibody

Ganitumab (Anti-IGF-1R / CD221) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. MW: 145.5 KD.

Ganitumab (Anti-IGF-1R / CD221)

Quality Control

Batch: Purity: 99% Protein concentration: 5.97mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation IGF-1R Insulin Receptor Others
Linsitinib (OSI-906) 210 IRR
NVP-AEW541 65 FLT3,Tek,FLT1
GSK1904529A 26
NVP-ADW742 24
BMS-536924 26 FAK,MEK,LCK
AG-1024 29
GSK1838705A 18 ALK
BMS-754807 54 TrkB,Met,TrkA
PQ 401 5
Ginsenoside Rg5 0
XL228 0 ABL T315I,LYN,Aurora A
Picropodophyllin (AXL1717) 48
AZD3463 8 ALK
S961 3
Nordihydroguaiaretic acid (NDGA) 2 p300,HER2,lipoxygenase
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Ganitumab (Anti-IGF-1R / CD221) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. MW: 145.5 KD.

Product Details

CAS No. 905703-97-1
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01042379 RECRUITING Drug: Standard Therapy|Drug: AMG 386 with or without Trastuz Breast Neoplasms; Breast Cancer; Breast Tumors; Angiosarcoma; TNBC - Triple-Negative Breast Cancer; HER2-positive Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Tumor; Hormone Receptor Negative Tumor; Early-stage Breast Cancer; Locally Advanced Breast Cancer QuantumLeap Healthcare Collaborative 2010-03-01 PHASE2
NCT04199026 RECRUITING Drug: Doxorubicin|Drug: Doxorubicin Hydrochloride|Drug: Ever Metastatic Sarcoma; Recurrent Sarcoma; Resectable Sarcoma M.D. Anderson Cancer Center 2025-02-25
NCT06866548 ACTIVE_NOT_RECRUITING Drug: anti-IGF-1R mAb (Teprotumumab/IBI311) + anti-PD-1 mAb mCRPC Shanghai Changzheng Hospital 2025-03-10 EARLY_PHASE1
NCT06269393 COMPLETED Drug: Placebo|Drug: IBI311 Thyroid Associated Ophthalmopathy Peking University People's Hospital 2024-01-01 PHASE3
NCT04129151 TERMINATED Drug: Palbociclib|Drug: Ganitumab Ewing Sarcoma; Ewing's Sarcoma Recurrent Dana-Farber Cancer Institute 2019-12-05 PHASE2
NCT03041701 TERMINATED Drug: Dasatinib|Drug: Dasatinib|Drug: Ganitumab Rhabdomyosarcoma; Rhabdomyosarcoma, Alveolar; Rhabdomyosarcoma, Embryonal National Cancer Institute (NCI) 2017-07-07 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2026-05-06)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.